TipRanks
SynAct Pharma AB (SE:SYNACT)
:SYNACT
Sweden Market
SYNACT
SynAct Pharma AB
RESEARCH TOOLSreports
Want to see SE:SYNACT full AI Analyst Report?

SynAct Pharma AB (SYNACT) Stock News & Sentiment

2 Followers
SynAct Pharma Launches Global Investor and Partnering Push
Premium
Company Announcements
SynAct Pharma Launches Global Investor and Partnering Push
9d ago
WHO Endorses SynAct Pharma’s Resomelagon as Key Dengue Drug Candidate
Premium
Company Announcements
WHO Endorses SynAct Pharma’s Resomelagon as Key Dengue Drug Candidate
15d ago
SynAct Pharma bolsters resomelagon data as it readies Phase 3 and weighs strategic deals
Premium
Company Announcements
SynAct Pharma bolsters resomelagon data as it readies Phase 3 and weighs strategic deals
24d ago
SynAct Pharma Executives Sell Shares to Cover Danish Tax Liabilities
Premium
Company Announcements
SynAct Pharma Executives Sell Shares to Cover Danish Tax Liabilities
28d ago
SynAct Pharma Expands Resomelagon’s Potential With New Preclinical Inflammation Data
Premium
Company Announcements
SynAct Pharma Expands Resomelagon’s Potential With New Preclinical Inflammation Data
1M ago
SynAct Pharma Details 2026 First-Half Progress in Inflammatory Disease R&D
Premium
Company Announcements
SynAct Pharma Details 2026 First-Half Progress in Inflammatory Disease R&D
1M ago
SynAct Pharma strikes first resomelagon commercial deal in Brazil’s dengue market
Premium
Company Announcements
SynAct Pharma strikes first resomelagon commercial deal in Brazil’s dengue market
1M ago
More SE:SYNACT News >

SYNACT News on the Web

WHO Endorses SynAct Pharma’s Resomelagon as Key Dengue Drug Candidate
TipRanks News
Bullish
SynAct Pharma bolsters resomelagon data as it readies Phase 3 and weighs strategic deals
TipRanks News
Bullish
SynAct Pharma Executives Sell Shares to Cover Danish Tax Liabilities
TipRanks News
Neutral
SynAct Pharma Expands Resomelagon’s Potential With New Preclinical Inflammation Data
TipRanks News
Bullish
SynAct preclinical data point to osteoarthritis potential for resomelagon
TipRanks News
Bullish
SynAct Pharma draws heightened partner interest as ADVANCE data boost resomelagon’s strategic appeal
TipRanks News
Bullish
SynAct Pharma Leadership Locks Up Shares Through 2026 to Signal Long-Term Confidence
TipRanks News
Bullish
SynAct Pharma’s AP1189 Trial Targets Viral Respiratory Risk: What Investors Should Watch
TipRanks News
Bullish

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average1.25 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is SE:SYNACT’s Media Buzz Sentiment?
Currently, no data Available
What is SE:SYNACT’s weekly average amount of articles?
In an average week, 1.25 articles about SE:SYNACT are published.
    What is SE:SYNACT’s News Sentiment?
    Currently, no data Available
    Healthcare Stocks that are Trending in the News
    XERSXeris Pharmaceuticals
    LGNDLigand Pharma
    MIRMMirum Pharmaceuticals
    AXSMAxsome Therapeutics
    ABBVAbbVie
    Showing the stocks with the most bullish news sentiment over the past week